Reuters: Health
Singapore's Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.
Temasek-backed Tychan to start human trials next week for COVID-19 treatment
Temasek-backed Tychan to start human trials next week for COVID-19 treatment
Reuters: Health
Singapore's Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.
Reuters: Health
Singapore's Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment